Ankaferd® Kanama Durdurucunun Rat Abdominal Aort Kanama Modelinde Kanama Zamanına Etkisi

<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"MS 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"MS 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-no-proof:yes;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Giriş: Topikal hemostatik ajanların birçok cerrahi alanda kullanımı son yıllarda popularite kazanmıştır. Ankaferd® kanama durdurucu (ABS) ajanın ratlarda abdominal aort cerrahisinde kanama zamanını kısaltıp, kanama miktarını azaltabildiğini belirt          meye amaçladık. Hastalar ve Yöntem: Toplam 40 rat random 4 gruba (her grup n= 10) ayrıldı. Grup 1 ve grup 2’deki ön-tedavi almayan ratlara salin ve Ankaferd kanama durdurucu ABS emdirilmiş gaz uygulanırken, 5 gün asetil salisilik asit ve klopidgrel tedavisi alış olan grup 3 ve 4’teki ratlara da salin ve ABS emdirilmiş gaz uygulandı. İliak bifurkasyonun üzerinde abdominal aortaya 1 mm’lik bir kesi yapıldı. Ortalama kanama zamanı ve ortalama kanama miktarı belirlenip karşılaştırıldı. Bulgular: Ratların yaş, ağırlık ve laboratuvar sonuçları karşılaştırıldığında gruplar arası anlamlı farklılık yoktu. ABS emdirilmiş gaz kullanılan hem tedavi uygulanmış hem de tedavi uygulanmamış gruplarda daha kısa kanama zamanı ve daha az kanama miktarı tespit edildi. Aradaki fark istatistiksel olarak anlamlı bulundu. Sonuç: Ankaferd® kanama durdurucunun major aort cerrahisi sonrası daha kısa kanama zamanı sağlama ve operasyon sonrası daha az kan kaybı sağlama potansiyeline sahiptir.
Anahtar Kelimeler:

Topikal hemostaz, abdominal aort

Haemostatic Effects of Topical Ankaferd Blood Stopper® On Bleeding Time in A Rat Abdominal Aortic Bleeding Model

<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"MS 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:1; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:variable; mso-font-signature:0 0 0 0 0 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-no-proof:yes;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Introduction: The use of topical haemostatic agents has been popularised in recent years in many areas of surgery. We aimed to determine whether Ankaferd blood stopper® (ABS) can shorten the bleeding time and decrease the amount of bleeding in a rat abdominal aortic bleeding model. Patients and Methods: A total of 40 rats were randomly divided into four groups (n= 10 in each group). Saline- and ABS-soaked gauzes were applied to rats that had not received any pre-treatment in Groups 1 and 2, while saline- and ABS-soaked gauzes were applied to rats that had received acetylsalicylic acid plus oral clopidrogel for 5 days in Groups 3 and 4. An incision of about 1 mm was made over the aorta just proximal to the iliac bifurcation. Mean bleeding time (MBT) and mean bleeding amount (MBA) were determined and compared. Results: There were no significant differences in the age, weight and blood sample laboratory results of rats. Shorter MBT and less MBA were determined in ABS-soaked groups and the differences were statistically significant. Conclusion: Ankaferd blood stopper® has the potential to reduce the bleeding time and post-operative blood loss after a major aortic surgery.

___

  • 1. Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010;251:217-28.
  • 2. Sileshi B, Achneck HE, Lawson JH. Management of surgical hemostasis: topical agents. Vascular 2008;16:S22-8.
  • 3. Haznedaroglu BZ, Beyazit Y, Walker SL, Haznedaroglu IC. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Crit Rev Oncol Hematol 2012;83:21-34.
  • 4. Aktas A, Er N, Onur MA. Effects of Ankaferd Blood Stopper (R) on vascular response in rat carotid artery. UHOD 2010;20:156-62.
  • 5. Kandemir O, Buyukates M, Kandemir NO, Aktunc E, Gul AE, Gul S, et al. Demonstration of the histopathological and immunohistochemical effects of a novel hemostatic agent, Ankaferd Blood Stopper, on vascular tissue in a rat aortic bleeding model. J Cardiothorac Surg 2010;5:110.
  • 6. Abacıoğlu S, Aydın K, Büyükcam F, Kaya U, Işık B, Karakılıç ME. Comparison of the efficiencies of buffers containing Ankaferd and chitosan on hemostasis in an experimental rat model with femoral artery bleeding. Turk J Haematol 2015 Apr 27.
  • 7. Karasoy Yeşilada A, Bayraktaroğlu SB, Sevim KZ, Sakız D, Tatlıdede HS. The efficacy of the hemostatic agent Ankaferd blood stopper on end-to-end unilateral sleeve fish-mouth anastomosis. Acta Orthop Traumatol Turc 2014;48:92-7.
  • 8. Saçak B, Akdeniz ZD, Şirinoğlu H, Çilingir ÖT, Çelebiler ÖB, Ercan F, et al. Microvascular anastomosis using Ankaferd blood stopper: demonstration of long-term histopathologic effects on vascular tissue. Blood Coagul Fibrinolysis 2014;25:721-5.
  • 9. Çakarer S, Eyüpoğlu E, Günes ÇÖ, Küseoğlu BG, Berberoğlu HK, Keskin C. Evaluation of the hemostatic effects of Ankaferd blood stopper during dental extractions in patients on antithrombotic therapy. Clin Appl Thromb Hemost 2013;19:96-9.
  • 10. Beyazit Y, Kart T, Kuscu A, Arslan A, Kurt M, Aktas B, et al. Successful management of bleeding after dental procedures with application of blood stopper: a single center prospective trial. J Contemp Dent Pract 2011;12:379-84.
  • 11. Iynen I, Bozkus F, San I, Alatas N. The hemostatic efficacy of Ankaferd Blood Stopper in adenoidectomy. Int J Pediatr Otorhinolaryngol 2011;75:1292-5.
  • 12. Guler M, Maralcan G, Kul S, Baskonus I, Yilmaz M. The efficacy of Ankaferd Blood Stopper for the management of bleeding following total thyroidectomy. J Invest Surg 2011;24:205-10.
  • 13. Meric Teker A, Korkut AY, Kahya V, Gedikli O. Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis. Eur Arch Otorhinolaryngol 2010;267:1377-81.
  • 14. Turhan N, Bilgili H, Captug O, Kurt M, Shorbagi A, Beyazit Y, et al. Evaluation of a haemostatic agent in rabbits. Afr J Tradit Complement Altern Med 2011;8:61-5.
  • 15. Nazli Y, Colak N, Alpay MF, Haltas H, Aksoy ON, Akkaya IO, et al. Assessment of the efficacy of Ankaferd blood stopper on the prevention of postoperative pericardial adhesions. Cardiovasc J Afr 2014;25:100-5.
  • 16. Mihmanli A, Ulker Z, Alpsoy L, Ezirganli S. Evaluation of cytotoxicity of a new hemostatic agent Ankaferd Blood Stopper® using different assays. Hum Exp Toxicol 2012;31:780-
Koşuyolu Heart Journal-Cover
  • ISSN: 2149-2972
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 1990
  • Yayıncı: Sağlık Bilimleri Üniversitesi, Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi
Sayıdaki Diğer Makaleler

Transfemoral Transkateter Aort Valv İmplantasyonu Sonrası Kontrast Bağımlı Nefropati Gelişiminde Femoral Giriş Yönteminin Önemi

İlker GÜL, Mustafa ZUNGUR, Ahmet TAŞTAN, Muhammed Esad ÇEKİN, Ahmet Çağrı AYKAN, Aysel İSLAMLI, Talat TAVLI

Akut Dekompanse Sistolik Kalp Yetersizliği Hastalarında BNP Değişimi ile Korele Ekokardiyografik Parametrelerin Araştırılması

Mehmet Akif Ekinci, Mehmet Eyüboğlu, Özer Badak

Importance of EuroSCORE-II in the Development of Acute Ischemic Heart Failure After Acute Anterior ST Elevation Myocardial Infarction

İlker GÜL, Ahmet Çağrı AYKAN, Mustafa ZUNGUR, Murat BİLGİN, Bekir Serhat YILDIZ, Aysel İSLAMLI

Association of Monocyte-to-HDL Cholesterol Ratio with Cardiac Syndrome X is Linked to Systemic Infl ammation

Selçuk PALA, Anıl AVCI, Elnur ALİZADE, Regayip ZEHİR, Mehmet Mustafa TABAKCI, Servet İZCİ, Ahmet GÜLER, Ahmet GÜNER

Tip 2 Diabetes Mellituslu Hastalarda Kardiyak Otonomik Nöropati ve Plasma Homosistein Seviyesi Arasındaki İlişki

Anıl AVCI, Mehmet Mustafa TABAKCI, Cüneyt TOPRAK, Elnur ALİZADE, Göksel AÇAR, Uğur ARSLANTAŞ, Ramazan KARGIN

Haemostatic Effects of Topical Ankaferd Blood Stopper® On Bleeding Time in A Rat Abdominal Aortic Bleeding Model

Oruç Alper ONK, Hüseyin Serkan EROL, Fatih ÖZÇELİK, Ümit KAHRAMAN, Didem ONK, Erdim SERTOĞLU, Bilgehan ERKUT, Osman Nuri TUNCER, Ömer YİĞİNER, Mehmet AKSÜT

The Mystery Hidden by Pulmonary Embolism: Colonic Adenocarcinoma

Mithat SELVİ, Sevil ÖNAY, Tarkan TEKTEN

Monositin HDL Kolesterole Oranının Kardiyak Sendrom X ve Sistemik İnflamasyon ile İlişkisi

Elnur ALİZADE, Anıl AVCI, Ahmet GÜNER, Mehmet Mustafa TABAKCI, Regayip ZEHİR, Ahmet GÜLER, Servet İZCİ, Selçuk Pala

Akut Anterior Miyokart İnfarktüsü Sonrası Akut İskemik Kalp Yetersizliği Gelişimini Öngörmede EuroSCORE-II’nin Önemi

İlker GÜL, Mustafa ZUNGUR, Ahmet Çağrı AYKAN, Aysel İSLAMLI, Bekir Serhat YILDIZ, Murat BİLGİN

Pulmoner Emboli Tarafından Saklanan Sır: Kolon Adenokarsinomu

Mithat SELVİ, Sevil ÖNAY, Tarkan TEKTEN